

WAYNE C. JONES, M.D.

CURRICULUM VITAE

WAYNE C. JONES M.D.

Texas License #D6049

Business Address	The Richardson Medical Park 375 Municipal Drive Suite 224 Richardson, Texas 75080 (972) 234-0489 FAX (972) 235-1558 email: info@askdrjones.com
Date of Birth	June 28, 1942
Hobbies	Competitive running, tennis
Education	
	1964-1968 M. D. University of Texas, Dallas, TX Southwestern Medical Branch
	1960-1964 B. A. University of Houston, Texas Psychology, Magna Cum Laude
Training	
	1969-1972 Presbyterian Hospital, Dallas, TX Parkland Memorial Hospital, Dallas Psychiatry Residency
	1968-1969 Presbyterian Hospital, Dallas, TX Internship in Internal Medicine and Psychiatry
Certification	
	May 1975 American Board of Psychiatry and Neurology Diplomate
	July 1969 National Board of Medical Examiners Diplomate
	Nov. 1998 Certified Clinical Psychopharmacologist by the American Society of Clinical Psychopharmacology
	May 2003 Certified Clinical Psychopharmacologist by the American Society of Clinical Psychopharmacology

PROFESSIONAL ORGANIZATIONS:

American Society of Clinical Psychopharmacologists
 Depressive/Manic Depressive Association of Dallas
 The OCD Foundation
 The Phobia Society of Dallas
 National Alliance for the Mentally Ill
 The OCD Association of Dallas
 Attention Deficit Disorder Association, Southern Region
 CHADD

POSITIONS/EXPERIENCE:

1981 – Present Richardson Medical Park, Richardson, Texas, Private Practice
 1993 – Present Speakers Bureau/Consultant
 Current: Wyeth, Cephalon, Glaxo Smith Kline, Bristol-Meyers, Schwarz,
 Sepracor, Astra Zeneca, Sanofi
 Past: Eli Lilly, Pfizer, Forrest, Novartis, McNeill, Solvay
 1993 – 2005 Psychiatric Consultant to the Student Counseling Service
 University of Texas at Dallas
 1982 – 2003 Medical Director
 Phobia and Anxiety Center of the Southwest
 1996 – 1998 Psychiatric Advisory Board, Pfizer Pharmaceuticals
 1994 – 1997 Psychiatric Medical Director
 United Insurance Companies, Inc., Student Insurance Division
 1975 – 1997 Staff Member, Richardson Medical Center, Richardson, Texas
 1996 – 1997 Professional Advisory Committee Member
 Attention Deficit Disorder, Southern Region
 1995 – 1997 Associate Medical Director
 Grace Community Health Care Day Hospital (Geriatric)
 1992 – 1996 National Advisory Committee Member
 Economic Cost of Treatment of Anxiety Disorders
 1992 – 1996 Patient Advocacy Committee Member
 North Texas Society of Psychiatric Physicians
 1992 – 1996 Public Affairs Committee, Texas Society of Psychiatric Physicians
 1996 “Going Sane with Dr. Jones” Radio Show on KRLD, 1080 AM

1987 – 1991 Officer, General Medical Staff (President, 1989)
Richardson Medical Center, Richardson, Texas

1990 Review Committee Member

1991 Clinical and Education/Self-Help Tracks

1991 National Conference on Phobias and Related Anxiety Disorders
Phobia Society of America

1985 – 1987 Medical Director of Psychiatry
Richardson Medical Center

1985 – 1988 Chairman, Department of Psychiatry

1982 – 1984 Richardson Medical Center

1984 – 1987 Clinical Assistant Professor
University of Texas Southwestern Medical School

1974 – 1984 Clinical Instructor
University of Texas Southwestern Medical School

June 1980 Group Psychotherapy Marathon, sixteen hours with Ruth McClendon, M.S.W.

1974 – 1975 Consultant, Veterans Administration; Bonham, Texas

1974 – 1977 Consultant, Texoma Mental Health Mental Retardation Clinic
Bonham, Texas

1972 – 1974 Consultant, Wichita Falls State Hospital

1972 – 1974 Major, United States Air Force
Sheppard Air Force Base Hospital, Wichita Falls, Texas.
Psychiatrist in charge of 30-bed unit for one year in largest inpatient
facility in the Air Force.

1969 – 1972 Part-time Emergency Room Physician
Presbyterian Hospital, Dallas, Texas

1968 – 1972 Personal Psychoanalysis, Dr. George Nicolaou

1966 – 1968 Psychiatry Externship, Parkland Hospital, Dallas, Texas
Community Mental Health Clinic and Community Center
Presbyterian Hospital, Dallas

1967 Research Assistant, Departments of Psychiatry and Obstetrics Gynecology
University of Texas Southwestern Medical School

1965 Research Assistant, Research in Neurophysiology
University of Texas Southwestern Medical School

1964 Research Assistant, Drug Efficacy Study
Terrell State Hospital, Terrell, Texas

PUBLICATIONS:

Publication of Newsletter, *Mental Fitness Update*, 1999 to present

Uhlenhuth, E. H., Alexander, Paul E., Dempsey, G. Michael, Jones, Wayne, Coleman, Bernard S., Swiontek, Ann M., Medication side effects in anxious patients: Negative placebo responses? *Journal of Affective Disorders* 47 (1998) 183-190

Sutton, D.L., New Body this Year, forward written by W.C. Jones., Dallas, Books for Your Benefit, 1995.

Carter, C.S., Fawcett, J, Hertzman, M., Jones, W.C., Patterson, W.M., Swinson, R.P., Swinson, R.P., Weise, C.C., Maddock, R.J., Sheridan, A.Q. and M. Liebowitz. Alprazolam-SR in Panic Disorder with Agoraphobia: Relationship of Daily Dose to Efficacy. *Journal of Clinical Psychiatry*, 1995.

Jones, W.C.: Medical Treatment of Anxiety Symptoms: An Update. Dallas AMI Newsletter. November, 1994.

Jones, W.C.; Generalized Anxiety: Psychiatry's Answer to High Blood Pressure, Ulcer, and Arthritis. The Quarterly Newsletter of the Phobia Center of the Southwest. Issue No. 4.

Jones, W.C. Medications alleviate anxiety symptoms. The Quarterly Newsletter of the Phobia Center of the Southwest. Fall, 1990.

Jones, W.C.: Understanding the role of personality disorders in the evaluation and treatment of major mental health disorders. Dallas AMI Newsletter October, 1993: 3.

Jones, W.C.: Medications and anxiety. ADAA Reporter. Winter, 1993: 11.

Richman, R. and W.C. Jones: Anxiety disorders in the workplace. The National Association of Women's Health Professionals Newsletter Winter, 1991.

Siegel, L., Jones, W.C., and J.O. Wilson: Economics and life consequences experienced by a group of individuals with panic disorders. *Journal of Anxiety Disorders*, Vol 4: 201-211, 1990.

Jones, W.C.: Relaxation responses are reactions. Richardson Daily News. December 2, 1985.

Willis, W.D., Willis, J.C., Thompson, W.M., and W.C. Jones: A descending pathway which is monosynaptically excitatory to mononeurons. *Nature*, 211: No 5054, 1182-1183, September 10, 1966.

Willis, W.D., Thompson, W.M., Jones, W.C., and J. C. Willis: Descending monosynaptic excitatory connections to spinal mononeurons. *Anat. Rec.*, 154: 441, 1966.

PRESENTATIONS – MEDIA EXPERIENCE:

Has given over 1,300 presentations to physicians and healthcare professionals as well as the general public. Presentation topics include: bipolar disorder, major depression, women's issues, elderly and refractory depression, ADHD, anxiety disorders, sleep disorders, the pathophysiology of stress disorders, and drug-drug interactions.

Hosted a radio talk show on KRLD called, "Going Sane with Dr. Jones" featuring stress-related current topics of interest from 2/3/96 to 5/25/96.

Has a website, www.askdrjones.com which is designed to be a resource on stress disorders.

PRINCIPAL INVESTIGATOR – CLINICAL DRUG TRIAL EXPERIENCE:

Feasibility study on panic using a palm pilot device to determine intensity and duration of panic attacks, 2003

"Celexa Clinical Experience Trial Program", 5 Subjects, 8-week clinical trial on depressed patients, 1998

"Doorways to Recovery" - Revia Patient Support Program, 1996

Nefazodone Clinical Experience Trial Program, 5 Subjects, 8-week clinical trial 1995

A Double Blind Placebo Controlled Dose Escalation Study of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with GAD, 15 subjects, 12 week treatment phase, with 12 week continuation phase, 1995.

Adderall clinical study, 1995.

"Safety Surveillance Study for Wellbutrin Sustained Release" 54 subjects, 8 week treatment phase, up to 12 month continuation phase, 1993.

"Xanax Tablets to Xanax XR Tablets Conversion in the Treatment of Clinical Anxiety" 15 subjects, 5 week treatment, 1993.

"Multicenter Trial to Evaluate the Efficacy and Safety of Sertraline in the Treatment of Major Depression" 15 subjects, 8 week treatment, 1992.

"Short- and Long-term Discontinuation of Alprazolam in the Treatment of Panic Disorder with Agoraphobia" 32 subjects, 6-9 month treatment, 1992-1993.

"Deracyn SR in the Treatment of Generalized Anxiety Disorder with Depressive Symptoms" 40 subjects, 11 week treatment, 1991.

"Collaborative Fixed-Dose Study of the Efficacy and Safety of Deracyn-SR Tablets in Panic Disorder with Agoraphobia" 48 subjects, 10 week treatment, 1990.